Core Viewpoint - The company plans to use part of the excess raised funds, amounting to RMB 30,400.00 million, to permanently supplement its working capital, ensuring that this does not affect the normal operation of the fundraising investment projects [4][6][7] Fundraising Basic Situation - The company was approved to publicly issue 14,785,700 shares at a price of RMB 125.88 per share, raising a total of RMB 186,122.39 million, with a net amount of RMB 166,635.87 million after deducting issuance costs [1][2] Investment Project Overview - The net amount raised is planned to be allocated as follows: - Intelligent Measurement and Control Equipment Production Base Project: RMB 31,728.35 million - R&D Center Project: RMB 14,815.13 million - Working Capital Supplement: RMB 14,000.00 million - Excess Funds: RMB 101,478.09 million - Total: RMB 166,635.87 million [3][4] Plan for Using Excess Funds - The company intends to use 29.96% of the total excess funds (RMB 30,400.00 million) for working capital, ensuring that the investment projects remain funded and operational [4][5] Impact and Commitments - The use of excess funds for working capital is aimed at improving efficiency, reducing financial costs, and enhancing profitability without altering the intended use of the raised funds [5][6] Approval Process - The proposal to use excess funds was approved by the company's board and supervisory committee and will be submitted for shareholder approval [6][7] Sponsor's Verification Opinion - The sponsor has no objections to the company's plan to use RMB 30,400.00 million of excess funds for working capital, confirming compliance with relevant regulations and that it will not harm shareholder interests [7]

Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., plans to use part of the excess raised funds to permanently supplement its working capital, which has been approved by its board and supervisory board, and will be submitted for shareholder approval [1][6]. Fundraising Overview - The company issued 21,508,335 shares at a price of 56.56 RMB per share, raising a total of 1,216,511,427.60 RMB, with a net amount of 1,110,744,306.58 RMB after deducting issuance costs of 105,767,121.02 RMB [1][2]. - The funds were deposited in a special account approved by the board, and a tripartite supervision agreement was signed with the sponsor and the bank [2]. Investment Project Details - The net amount raised is 111,074.43 million RMB, with 99,718.47 million RMB allocated to the project for producing 190 tons of high-end pharmaceutical products, leaving an excess of 31,074.43 million RMB [3]. Previous Use of Excess Funds - The company has previously used 18,000 million RMB of excess funds for permanent working capital, with the latest approval for an additional 9,000 million RMB to be used for the same purpose [4][6]. Current Plan for Excess Funds - The company intends to use 9,000 million RMB of excess funds for permanent working capital, which constitutes 28.96% of the total excess funds, and will not exceed 30% [5]. - This plan will be implemented after the previous use of excess funds has been completed for 12 months, ensuring compliance with regulatory requirements [5]. Commitments and Explanations - The company commits that the cumulative use of excess funds for working capital will not exceed 30% of the total excess funds and will not affect the funding needs of investment projects [5][6]. Review Procedures and Opinions - The board and supervisory board have approved the use of excess funds for working capital, stating that it will enhance the efficiency of fund usage without affecting investment projects [6][7].

Core Viewpoint - Tianfeng Securities has conducted a special review regarding Guangdong Jushi Chemical Co., Ltd.'s return of raised funds and the use of remaining over-raised funds for permanent working capital supplementation, confirming compliance with relevant regulations and the interests of the company and its shareholders [1][7]. Summary by Sections 1. Basic Situation of Raised Funds - Guangdong Jushi Chemical was approved to publicly issue 23,333,334 shares at a price of RMB 36.65 per share, raising a total of RMB 855.1667 million, with a net amount of RMB 775.7297 million after deducting issuance costs of RMB 79.4370 million [1][2]. 2. Return of Temporarily Used Funds - The company temporarily used up to RMB 90 million of idle raised funds for working capital, which was approved by the board and returned to the special account by the date of the review [2][6]. 3. Investment Project Overview - The total investment amount for the projects funded by the raised funds is RMB 490.4617 million, with the net amount of raised funds being RMB 775.7297 million, resulting in a total over-raised amount of RMB 285.2680 million [2][4]. 4. Use of Over-raised Funds - The company plans to use RMB 43.5844 million of the remaining over-raised funds for permanent working capital, which accounts for 15.28% of the total over-raised funds [5][6]. 5. Compliance and Commitments - The company commits that the cumulative use of over-raised funds for permanent working capital will not exceed 30% of the total over-raised funds within any twelve-month period, ensuring that this will not affect the funding needs of investment projects [6][7]. 6. Review Procedures - The proposal for using the remaining over-raised funds for permanent working capital has been approved by the board and is pending submission to the shareholders' meeting for further approval [6][8]. 7. Sponsor's Review Opinion - Tianfeng Securities has no objections to the company's plan to use remaining over-raised funds for permanent working capital, confirming that the necessary review procedures have been followed and that there is no change in the purpose of the raised funds [7][8].

Group 1 - The board of directors of Guangdong Jushi Chemical Co., Ltd. held its second meeting of the seventh session on August 18, 2025, with all 9 directors present, ensuring compliance with relevant laws and regulations [1][2][3] - The board approved the proposal to use remaining raised funds totaling 43.5838 million RMB for permanent working capital, which accounts for 15.28% of the total raised funds [1][2] - The board also approved a special report on the use of previously raised funds, which was verified by Zhongxinghua Accounting Firm [2] - A proposal for the third extraordinary shareholders' meeting scheduled for September 3, 2025, was also approved [2][3]

格隆汇8月18日丨聚石化学(688669.SH)公布，2025年8月18日，公司召开第七届董事会第二次会议审议 通过了《关于使用剩余超募资金永久补充流动资金的议案》，同意公司使用剩余超募资金总计4,358.38 万元人民币用于永久补充流动资金。本次拟用于永久补充流动资金的超募资金占超募资金总额的 15.28%。 ...

Core Viewpoint - The company, Maolai Optical, has made significant decisions regarding its financial management and operational strategies, including the use of idle funds for wealth management and the initiation of foreign exchange hedging activities. Group 1: Stock Performance - As of August 15, 2025, Maolai Optical's stock closed at 353.44 yuan, reflecting a 5.66% increase from the previous week's closing price of 334.52 yuan [1] - The stock reached a weekly high of 361.99 yuan on August 14 and a low of 321.28 yuan on August 12 [1] - The company's current total market capitalization is 18.662 billion yuan, ranking 12th out of 92 in the optical and optoelectronic sector and 973rd out of 5,152 in the A-share market [1] Group 2: Board and Supervisory Decisions - The fourth board of directors held its 13th meeting on August 13, 2025, where several key resolutions were passed, including the use of idle funds for wealth management and the initiation of foreign exchange hedging transactions [1][2] - The supervisory board also convened on the same day, approving similar resolutions regarding the use of idle funds and foreign exchange hedging, emphasizing the benefits of these actions for the company's financial stability [2] - A notice was issued for the second extraordinary shareholders' meeting of 2025, scheduled for September 12, 2025, to discuss the use of excess funds and the reappointment of the auditing firm [2] Group 3: Financial Management Initiatives - The company plans to use up to 100 million yuan of its idle funds for wealth management, focusing on low-risk, high-liquidity investment products [3] - A proposal was made to use 12.3 million yuan of excess funds to permanently supplement working capital, which constitutes 29.90% of the total excess funds [5] - The company intends to engage in foreign exchange hedging transactions with a limit of 100 million yuan, using its own funds and not involving speculative activities [3]

Core Viewpoint - The company plans to use CNY 35 million of its excess raised funds to permanently supplement its working capital, which accounts for 29.73% of the total excess funds raised [1][3][4]. Fundraising Overview - The company successfully raised a total of CNY 510 million through its initial public offering (IPO), issuing 17 million shares at CNY 30 per share, with a net amount of CNY 458.57 million after deducting issuance costs of CNY 51.43 million [1][2]. - The total investment amount for the projects funded by the raised capital is CNY 340.84 million, leaving an excess of CNY 117.73 million after accounting for project needs [2][3]. Use of Excess Funds - As of June 30, 2025, the company has utilized CNY 35 million of the excess funds for permanent working capital, leaving a balance of CNY 83.74 million [3][4]. - The decision to use part of the excess funds for working capital is aimed at improving operational efficiency and reducing financial costs while ensuring that the original fundraising projects remain unaffected [3][5]. Approval Process - The proposal to use excess funds for working capital has been approved by the Audit Committee and the Board of Directors, confirming that it does not conflict with the implementation of the fundraising projects [5][6]. - The proposal is pending approval from the shareholders' meeting before implementation [6].

Summary of Key Points Core Viewpoint - The company, Hebei Keli Automotive Equipment Co., Ltd., is utilizing part of the excess raised funds to permanently supplement its working capital, which has been approved by its board and supervisory committee, and is in compliance with relevant regulations [1][3][5]. Group 1: Fundraising Overview - The company successfully raised a total of RMB 510 million by issuing 17 million shares at a price of RMB 30 per share, with a net amount of RMB 458.57 million after deducting issuance costs of RMB 51.43 million [1][2]. - The total investment amount for the projects funded by the raised capital is RMB 340.84 million, leaving an excess of RMB 117.73 million after accounting for the project funding needs [2][3]. Group 2: Use of Excess Funds - The company plans to use RMB 35 million of the excess funds, which constitutes 29.73% of the total excess funds, to permanently supplement its working capital [3][4]. - As of June 30, 2025, the company has utilized RMB 35 million of the excess funds, leaving a balance of RMB 83.74 million, including interest income and cash management returns [3][5]. Group 3: Justification and Compliance - The decision to use excess funds for working capital is aimed at meeting the company's liquidity needs, improving fund utilization efficiency, reducing financial costs, and enhancing profitability, all while safeguarding the interests of the company and its shareholders [3][5]. - The company has committed to ensuring that the amount used for working capital does not exceed 30% of the total excess funds within any 12-month period and will not affect the implementation of the fundraising investment projects [5][6].

证券代码：301552 证券简称：科力装备 公告编号：2025-027 河北科力汽车装备股份有限公司 第三届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 河北科力汽车装备股份有限公司（以下简称"公司"）第三届董事会第二次 会议于 2025 年 8 月 14 日在公司会议室以现场与通讯相结合的方式召开。会议通 知于 2025 年 8 月 1 日以电子邮件的方式向全体董事和与会人员发出。本次会议 应出席董事 9 人，实际出席董事 9 人，全体高级管理人员列席了会议。会议由董 事长张万武先生召集并主持，会议的通知、召集、召开和表决程序符合《中华人 民共和国公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事认真审议，形成以下决议： 表决结果：同意 9 票；反对 0 票；弃权 0 票。 具体内容详见公司同日在巨潮资讯网（http://www.cninfo.com.cn）披露的《关 于使用部分超募资金永久性补充流动资金的公告》（公告编号：2025-030）。 保荐人长江证券承销保荐有限公司出具了核查意 ...

Group 1 - The board of directors of Nanjing Maolai Optical Technology Co., Ltd. held its 13th meeting of the 4th session on August 13, 2025, with all 6 directors present, ensuring compliance with relevant laws and regulations [1] - The board approved the proposal to use part of the idle self-owned funds for entrusted wealth management, which had been reviewed by the audit committee prior to the meeting [2] - The board also approved the proposal to conduct foreign exchange derivative hedging transactions, which was similarly reviewed by the audit committee [2] Group 2 - The board approved the proposal to permanently supplement working capital with part of the over-raised funds, aiming to meet liquidity needs and improve the efficiency of fund usage [3] - The board agreed to reappoint Gongzheng Tianye Accounting Firm as the auditing institution for the year 2025, pending shareholder meeting approval [3] - The board proposed to convene the second temporary shareholders' meeting of 2025, which does not require shareholder approval [3]